

## KSN 2017 Abstract

KSN-17-P226

### The effects of pazopanib versus sunitinib on renal outcome in metastatic renal cell carcinoma

Eun jeong LEE, \*Jung eun LEE

Nephrology, Samsung Medical Center, Korea, South

**Objectives** : Pazopanib and sunitinib are used as the first-line treatment of metastatic renal cell carcinoma (mRCC). With clinical outcome of mRCC has been improved by current targeted therapies, proper selection of therapy and management of toxicities are highlighted recently. Several studies have reported similar efficacy with a favorable safety profile of pazopanib. The aim of this study was to compare the renal outcome after pazopanib versus sunitinib treatment in patients with mRCC

**Methods** : We reviewed medical records of 304 patients with metastatic renal cell carcinoma who received pazopanib (n=103) or sunitinib (n=201) therapy from 2007 to 2016. Chronic kidney disease (CKD) progression was defined as a drop in glomerular filtration rate (GFR) category accompanied by a 25% or greater drop in GFR from baseline, during treatment. We compared the proportion of CKD progression between two groups and evaluated related risk factors among patients who received drugs more than 1 month. We also evaluated estimated GFR as time sequence between two groups.

**Results** : Overall, 47% of subjects had CKD stage 3 or 4 at baseline. Distributions of CKD stage were similar between two treatment groups. Treatment durations were 363 (129 ~ 504) days in pazopanib group and 360 (91 ~ 510) days in sunitinib group. Incidence of CKD progression was 19% in pazopanib group 17% in sunitinib group at 1 year after treatment ( $p = 0.083$  by log rank test). Lower serum albumin levels and older age were independent risk factors of CKD progression. There was no statistical difference between two groups in deterioration of estimated GFR as time sequence at baseline, 3 month, 6 month, 12 month after treatment ( $p = 0.464$ , by mixed linear mixed model)

**Conclusions** : The effects of pazopanib versus sunitinib treatment on CKD progression were similar in real-world practice. We suggest that there is no preference for selection of first line treatment for mRCC with regards to renal impairment.

**Keywords** : renal cell carcinoma, pazopanib, sunitinib, chronic kidney disease